Interleukin-22: A likely target for treatment of autoimmune diseases

Xuyan Yang, Song Guo Zheng

Research output: Contribution to journalReview articlepeer-review

85 Scopus citations


Interleukin-22 (IL-22) is a member of IL-10 family cytokines that is produced by many different types of lymphocytes including both those of the innate and adaptive immune systems. This includes activated T cells, most notably Th17 and Th22 cells, and NK cells, γδ T cells, LTi cells and LTi-like cells. IL-22 mediates its effects via the IL-22-IL-22R complex and subsequent Janus kinase-signal transducer and activators of transcription (JAK-STAT) signaling pathway. Recently accumulated evidence has indicated that IL-22 also plays an important role in the pathogenesis of many autoimmune diseases. In this review, we discuss the recent findings and advancement of the role for IL-22 in several autoimmune diseases, such as psoriasis, rheumatoid arthritis (RA), hepatitis, graft versus host disease (GHVD) and allergic diseases, implicating that target IL-22 may have a therapeutic potential in those autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)615-620
Number of pages6
JournalAutoimmunity Reviews
Issue number6
StatePublished - Jun 2014

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Interleukin-22: A likely target for treatment of autoimmune diseases'. Together they form a unique fingerprint.

Cite this